Trials / Completed
CompletedNCT02722265
Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
Open-label, Multicenter, Interventional, Dose Titration Study to Assess the Long-term Study of CS-3150 2.5mg and 5mg Alone as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 368 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration of CS-3150 as monotherapy and in combination with calcium channel blocker or renin-angiotensin system inhibitor in patients with essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-3150 | CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-07-08
- Completion
- 2017-07-08
- First posted
- 2016-03-29
- Last updated
- 2019-10-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02722265. Inclusion in this directory is not an endorsement.